Efficacy and safety of adalimumab 80 mg in the treatment of psoriasis: a bicentric retrospective study.
Por:
Sabater-Abad, J, Matellanes-Palacios, M, Bou-Boluda, L, Messeguer-Badia, F, Agusti-Mejias, A, Velasco-Pastor, M, Lorente-Fernandez, L and Gimeno-Carpio, E
Publicada:
1 may 2020
Ahead of Print:
29 abr 2020
Resumen:
Adalimumab (ADA) is a recombinant human monoclonal antibody indicated for the treatment of psoriasis that specifically inhibits tumor necrosis factor. Until recently we only had the presentation of 40 mg of ADA, being the standard dose in adults an initial administration of 80 mg, followed by 40 mg every 2 weeks. Newly the presentation of 80 mg of ADA has been commercialized, allowing the administration of the standard dose or a higher dose, with fewer injections. In this study, we retrospectively studied 11 patients with psoriasis who have received treatment with the presentation of 80 mg of ADA in two dermatology departments of two hospitals in Spain since its commercialization until June 2019. At the end of the study, an improvement in the mean final Psoriasis Area Severity Index (PASI) of all patients was observed, without any patient presenting any adverse effects. This study shows the efficacy and safety of 80 mg of ADA in a sample of 11 patients with psoriasis.
Filiaciones:
:
Hosp Arnau Vilanova, Dept Dermatol, C San Clemente 12, Valencia 46015, Spain
:
Hosp Arnau Vilanova, Dept Dermatol, C San Clemente 12, Valencia 46015, Spain
:
Hosp Arnau Vilanova, Dept Dermatol, C San Clemente 12, Valencia 46015, Spain
:
Hosp Virgen de los Lirios, Dept Dermatol, Alicante, Spain
:
Hosp Virgen de los Lirios, Dept Dermatol, Alicante, Spain
:
Hosp Arnau Vilanova, Dept Dermatol, C San Clemente 12, Valencia 46015, Spain
:
Hosp Arnau Vilanova, Dept Hosp Pharm, Valencia, Spain
:
Hosp Arnau Vilanova, Dept Dermatol, C San Clemente 12, Valencia 46015, Spain
gold
|